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Abstract  
 
Dose-response models express the effect of different dose or exposure levels on a specific 
outcome. In meta-analysis, where aggregated-level data is available, dose-response evidence 
is synthesized using either one-stage or two-stage models in a frequentist setting. We propose 
a hierarchical dose-response model implemented in a Bayesian framework. We present the 
model with cubic dose-response shapes for a dichotomous outcome and take into account 
heterogeneity due to variability in the dose-response shape.  We develop our Bayesian model 
assuming normal or binomial likelihood and accounting for exposures grouped in clusters. We 
implement these models in R using JAGS and we compare our approach to the one-stage dose-
response meta-analysis model in a simulation study. We found that the Bayesian dose-response 
model with binomial likelihood has slightly lower bias than the Bayesian model with the 
normal likelihood and the frequentist one-stage model. However, all three models perform very 
well and give practically identical results. We also re-analyze the data from 60 randomized 
controlled trials (15,984 participants) examining the efficacy (response) of various doses of 
antidepressant drugs. All models suggest that the dose-response curve increases between zero 
dose and 40 mg of fluoxetine-equivalent dose, and thereafter is constant. We draw the same 
conclusion when we take into account the fact that five different antidepressants have been                                                                                            
studied in the included trials. We show that implementation of the hierarchical model in 
Bayesian framework has similar performance to, but overcomes some of the limitations of the 
frequentist approaches and offers maximum flexibility to accommodate features of the data. 
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1 Introduction  
 
Dose-outcome associations examine the effect of different levels of exposure (for example, 
levels of smoking or drug doses) on a health outcome [1, 2]. In pairwise meta-analysis [3–5], 
combining dose-response associations from different studies and settings may lead to more 
precise and generalizable conclusions [6]. When aggregate-level data are available from 
multiple studies, dose-response associations can be synthesized using either a one-stage or two-
stage model. The one-stage model is implemented as a linear mixed model, which estimates a 
dose-response fixed effect and accounts for the heterogeneity by allowing slopes to vary across 
studies [7]. In a two-stage model, the dose-response model is fitted first within each study, and 
then the regression coefficients (or shape characteristics) are synthesized across studies [8–10].  
The one-stage model takes into account heterogeneity but provides relevant information 
via the estimate of a between-studies variance-covariance matrix. The two-stage model 
employs standard meta-analytical techniques and provides the usual heterogeneity measures, 
such as I2, in case this is of interest. However, to fit non-linear shapes, frequentist 
implementation of the two-stage model requires multiple dose levels to be reported in each 
study. For example, if the dose-response curve is assumed to be approximated by a 𝑝-order 
polynomial, all studies need to report outcomes for at least 𝑝 + 1 dose levels. This situation 
will result in excluding studies that report 𝑝 dose levels or fewer levels.  
The one-stage and two-stage models are implemented in a frequentist setting, and their 
performance has been evaluated in simulations and examples [11]. Fitting dose-response meta-
analysis in a Bayesian framework, in the form of a hierarchical model, is, in our view, highly 
desirable. First, Bayesian models [12, 13] can be easily extended to incorporate, for example, 
study-specific covariates, to combine observational and randomized data, or to deal with 
multiple outcomes and exposure types. Second, one can employ informative priors for the 
dose-response shape to reflect expert knowledge or evidence from external data sources. Third, 
one can easily extend the model to explore the variation in dose-response curves within and 
across groups of similar exposures or drugs.  Finally, probabilistic statements follow naturally 
as the posterior distributions can be interpreted as the true distributions of quantities of interest 
[14, 15].  
The paper is structured as follow. In Section 2 we present a Bayesian hierarchical dose-
response meta-analysis model with normal or binomial likelihood and the cluster-specific dose-
response model. The evaluation of the properties of the models follows in Section 3, alongside 
comparisons with the frequentist model in a simulations study. In Section 4, we re-analyse a 
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dataset of the dose-response association of various doses of antidepressants. Finally, we discuss 
the strengths and limitations of the model in Section 5. 
2 Methods 
We introduce a Bayesian hierarchical model for dose-response meta-analysis. We focus on a 
dichotomous outcome, although the models could easily accommodate continuous outcomes.  
2.1 Notation 
Table 1 summarizes the notation. Suppose there are 𝑛𝑠 studies (𝑖 = 1,… , 𝑛𝑠) and each study 
has a number of doses 𝑛𝑑! (𝑗 = 1,… , 𝑛𝑑!). Each study reported an empirical estimate of the 
outcome at each dose level. The doses are denoted by		𝑋!" where the minimum dose 𝑋!# is set 
as the reference level (control group). The observed outcome is expressed as number of events 
out of total observed or relative treatment effects. The dose-specific number of events is 𝑟!" out 
of a total sample size 𝑛!". The estimated change in the outcome from the reference dose 𝑋!# to 
dose 𝑋!", summarized for the 𝑛!" participants, is indicated by 𝑌!" 	 . 𝑌!" 	can be log odds ratio 
(logOR), log risk ratio (logRR), log hazard ratio (logHR), or any relative treatment effect for 
continuous outcomes such as mean difference. Relative effects rather than number of events 
are commonly reported in the context of studying environmental exposures or other exposures 
examined in observational studies [16]. In this case, the relative effects 𝑌!" 	 are the estimates 
from multivariable models adjusted for possible confounding variables. The vector 𝒀𝒊 =1𝑌!%, 𝑌!&, … , 𝑌!(()!*%)2 comprises all relative effects, on a natural logarithmic scale, for study 𝑖.  
 
2.2 Dose-response meta-analysis model 
We propose a hierarchical two-level model.  In the first level, the dose-response model is fitted 
within each study assuming either normal (normal dose-response model) or binomial 
likelihood (binomial dose-response model) for the observed data. In the second level, we 
synthesize the dose-response regression coefficients across studies. The hierarchical structure 
allows coefficients to borrow strength across studies, via the exchangeability assumption. 
2.2.1 Dose-response model within each study 
Within each study 𝑖, a multivariate normal distribution is assumed for 𝒀𝒊  𝒀𝒊	~	𝑀𝑉𝑁(𝜟𝒊, 𝑺𝒊), 
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where the vector 𝜟𝒊 = (𝛿!%	, … , 𝛿!(()!*%)) contains the underlying relative effects of dose 𝑋!" 
relative to dose 𝑋!#. The (𝑛𝑑!-1)	×(𝑛𝑑!-1) variance-covariance matrix 𝑺𝒊 can be estimated 
assuming a multinomial distribution for the number of events per dose and using the delta-
method for large sample sizes [17, 18]. For logOR, the elements of 𝑺𝒊 are 𝜎&> !", = ? 1/𝑟!# + 1/𝑡!#, 𝑖𝑓	𝑗 ≠ 𝑚1/𝑟!" 	+ 1/𝑡!" 	+ 	1/𝑟!# + 1/𝑡!#, 𝑖𝑓	𝑗 = 𝑚 , 
where 𝑡 refers to the number of non-events and the zero index refers to the quantities in the 
reference dose. The formula above is suitable when the logORs are estimated from 2x2 tables. 
If the logORs originate from adjusted logistic models from observational studies, then a 
correction in the correlations between dose strata should be applied to 𝑺𝒊, using the Longnecker 
and Greenland method [9, 10] or the approach suggested by Hamling [19]. 
If the data are from a randomized trial and the table of counts is available, it is 
straightforward to assume a binomial distribution of events 𝑟!"~𝐵𝑖𝑛𝑜𝑚1𝑝!" , 𝑛!"2, 
where 𝑝!" are the underlying probabilities of having an event in dose 𝑗 within study 𝑖. Then 
the underlying relative treatment effects are parametrised as 𝜆(𝑝!#) = 𝑢! 𝜆1𝑝!"2 = 𝑢! + 𝛿!", 
with 𝛿!" defined as above. The function 𝜆	is specified based on the effect size we want to 
estimate; for example, it is the logit function for logOR and the log function for logRR. The 
parameter  𝑢! is the log-odds of the event in the reference dose level.  
Note that continuous outcome data can be accommodated if 𝒀𝒊  are mean differences or 
standardized mean differences. Alternatively, if the outcome is available for each dose level, 
the normal likelihood is used instead of the binomial, and 𝛿!" is parameterized as the mean 
difference or standardized mean difference.  
2.2.2 Dose-response functions 
The underlying relative effect 𝛿!" can be modelled as 𝛿!" = 𝑓1𝑋!"; 𝑋!#; 	𝜷𝒊2, 
where 𝑓 is the dose-response function and 𝜷𝒊 are the shape parameters that need to be 
estimated. Note that the 𝑓 function could also be any transformation, including linear, 
quadratic, cubic or fractional polynomials and resulting in 𝜷𝒊 = (𝛽-!) being a vector of length 𝑝 and 𝑘 = 1,2, … , 𝑝 [20]. The simplest case is to assume a linear (𝑓 is the identity function)  
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shape 𝑝 = 1 where the statistical model needs to estimate only one parameter in study 𝑖;  𝜷𝒊 =	𝛽! and  𝛿!" = 𝑓1𝑋!"; 𝑋!#; 	𝛽!2 = 𝛽! 	(𝑋!" − 𝑋!#). However, investigating dose-response 
relations underlying several studies may require non-linear models. A flexible choice is using 
restricted cubic splines [21].  With 𝑚 knots, there are 𝑝 = 𝑚 − 1 regression coefficients in	𝜷𝒊 
to be estimated. Setting 𝑚 = 3, will result into 𝑓 consisting of 𝑝 = 2 dose-transformations; 𝑓% 
is the identity function and 𝑓& the restricted cubic spline transformation [21] with 
coefficients	𝜷𝒊 = (𝛽%! , 𝛽&!).  𝛿!" = 𝛽%!{𝑓%(𝑋!") − 𝑓%(𝑋!#)} + 𝛽&! 	{𝑓&(𝑋!") − 𝑓&(𝑋!#)}. 
2.2.3 Synthesize dose-response functions across studies 
In dose-response meta-analysis, the study-specific regression coefficients 	𝜷𝒊 = (𝛽%! , 𝛽&! , … )  
can then be synthesized.  Random dose-response coefficients model assumes that the 
underlying study-specific coefficients		𝜷𝒊		are normally distributed with mean 𝑩 =(𝐵%, 𝐵&, …𝐵.	) and variance-covariance matrix, 𝜮, that is  	𝜷𝒊~	𝑀𝑉𝑁(𝑩, 𝜮	). 
This model acknowledges the presence of a distribution of true dose-response relationships 
underlying the studies and is capable of predicting study-specific curves by borrowing strength 
from their variation across studies. 𝜮 is a 𝑝 × 𝑝 variance-covariance matrix with diagonal 
elements  𝜏.&	 and in the off-diagonal there are the 𝑝 − 1 covariances between the coefficients.  
To improve estimation, we will assume that 𝜏.& = 𝜏&	 and we will explore whether the 
correlations 𝜌 in 𝛴 are different from zero. Note that this model assumes that the heterogeneity 
across the study-specific estimates is fully captured by heterogeneity in the dose-response 
shapes. For a model with a common dose-response coefficient we set		𝜷𝒊 = 𝑩.  
2.3 Dose-response meta-analysis model accounting for clustering in the 
exposure  
Consider an exposure (or drug) variable that can take on different values. For example, daily 
intake of omega 3 fatty acids in relation to risk of cardiovascular events, possibly accounting 
for the different assessment of omega 3 (food supplements versus diet with fish and nuts). The 
differences between these two dose-response curves can be modelled by inserting type-specific 
regression coefficients	𝜷𝒊𝒄 = (𝛽%!0 , 𝛽&!0 , …	𝛽.!0 )	, where 𝑐 = {	1:	food	supplements, 2:	diet	with	fish	and	nuts}. 
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Overall, for a random of exposure clusters 𝑐 = 1,2, … , 𝐶 the relative effects are mapped 
to the transformed dose as  𝛿!" = 𝑓1𝑋!"; 𝑋!#; 	𝜷𝒊𝒄2. 
Next, 𝜷𝒊𝒄,		the vectors of coefficients from study	𝑖 examining the same cluster of exposures, are 
synthesised using a multivariate normal distribution with a common mean 𝑩𝒄 =(𝐵%0 , 𝐵&0 , …𝐵.0 	)		 and variance-covariance matrix 𝜮𝒘𝒊𝒕𝒉𝒊𝒏 ; that is a 𝑝 × 𝑝	matrix with diagonal 𝜏5!67!(&  and on the off-diagonal the 𝑝 − 1 covariances between the coefficients 𝜷𝒊𝒄~	𝑀𝑉𝑁1𝑩𝒄	, 𝜮𝒘𝒊𝒕𝒉𝒊𝒏	2. 
At the next step, the cluster-specific dose-response associations 𝑩𝒄	are synthesised across the	𝐶 
clusters. Again, a multivariate normal distribution with mean vector 𝑩	and variance-covariance 
matrix	𝜮𝒃𝒆𝒕𝒘𝒆𝒆𝒏	 is employed. 𝜮𝒃𝒆𝒕𝒘𝒆𝒆𝒏 has the same dimension as 𝜮𝒘𝒊𝒕𝒉𝒊𝒏 and in the diagonal 
the parameter 𝜏:;65;;(&  measures the heterogeneity between the clusters 	𝑩𝒄~	𝑀𝑉𝑁1𝑩	, 𝜮𝒃𝒆𝒕𝒘𝒆𝒆𝒏	2 
2.4 Predictions for the absolute response to a dose 
Predictions are easy to make within a Bayesian model as the total uncertainty in the parameters 
is propagated in the final predictions. Assume there is a natural reference dose, such as a dose 
zero or no-exposure. The observations	𝑟!#, , 𝑛!# from the zero dose levels can be parametrised 
to estimate an average summary response to zero-dose 𝑅# 𝑟!#~𝐵𝑖𝑛𝑜𝑚(𝑝!#, 𝑛!#), 𝜆(𝑝!#)~𝑁(𝑅#, 𝜎#&). 
Then, the estimate 𝑅# (measured on the log or logit probability scale) can be combined 
with 𝑩 to obtain the absolute response to any given dose level 𝑋" 𝜆*%k𝐵%{𝑓%(𝑋") − 𝑓%(𝑋#)} + 𝐵&	{𝑓&(𝑋") − 𝑓&(𝑋#)} + 𝑅#l 
2.5 Bayesian estimation 
We will use Markov chain Monte Carlo (MCMC) techniques to estimate all parameters in a 
Bayesian setting. An approximate non-informative prior distribution is chosen for the 
coefficients and the baseline effects 𝑢!# = logit	(𝑝!#) in the binomial model  𝐵-~𝑁(0, 10<) 𝑢!#~𝑁(0, 10<). 
Given that both in the simulations and in the example our outcome is dichotomous and 
measured on the natural log scale, we place a half-normal prior to the heterogeneity parameter  
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𝜏~	𝑁#(0,1)  
For correlations 𝜌 in the off-diagonal of the variance-covariances matrices, we use a uniform 
prior: 𝜌~𝑈𝑛𝑖𝑓(−1,1). 
 All Bayesian models are implemented in JAGS within R [22, 23]. The codes can be 
found in GitHub at https://github.com/htx-r/DoseResponsePMA. To obtain the spline 
transformations, we use the rcs function from the rms package [24]. To evaluate the 
convergence of the models we employed various diagnostic tools for MCMC included in the 
coda package [25]. We explored convergence plots for the MCMC (histograms, trace plots, 
Geweke plot and Gelman-Rubin plot) and relevant statistics (Raftery and Lewis statistic and 
Heidelberger and Welch test) [26]. 
3 Simulations study 
We aim to investigate the agreement between the estimations of the dose-response meta-
analysis curve under our two Bayesian models, assuming random-effects for the coefficients, 
and the frequentist one-stage model [27]. The codes are available in GitHub.  
3.1 Simulation design 
We assumed a true restricted cubic spline dose-response relationship with 3 knots at fixed 
percentiles (25th, 50th, and 75th) of the dose. We modelled the logOR and the logRR. 
For 40 clinical trials, we simulated study-level aggregated data. For each study, we 
simulated two non-zero doses from uniform distribution 𝑋!"~𝑈(1 ,10) and assumed each study 
reported one zero dose.  The study-specific coefficients 𝛽!% and 𝛽!& are generated independently 
from univariate normal distribution with means 𝐵% and 𝐵&, respectively, and common 
heterogeneity 𝜏. We chose true coefficient values that cover a reasonable range for ORs (0.3 to 
5) and we considered different dose-response shapes (see Appendix Figure 1). We introduced 
between-study heterogeneity, 𝜏 = 0.001, 0.01. The assumed mean and heterogeneity values 
result in eight scenarios, as shown in Table 2.  
Using 𝛽%!, 𝛽&! and 𝑋!" 	,	we calculated the underlying treatment effect 𝛿!" = log𝑂𝑅!" . To 
improve computing time, we assumed that the two shape coefficients 𝛽%! and 𝛽&! are unrelated 
(𝜌 = 0). Per dose, the observed number of events 𝑟!" are generated from binomial distributions 
with probability 𝑝!" and sample size 𝑛!". The event rate in the zero-dose group 𝑝#	is set to 0.1. 
The underlying event rate at dose 𝑗 is 𝑝!" = exp	(𝛿!") × 𝑝#. The sample size per dose is 
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generated from a uniform distribution 𝑛!"~𝑈𝑛𝑖𝑓(180,220) . In this way, the number of events 
and sample size per dose for each study are generated and used as input for the Bayesian 
binomial model. Using these counts, we then estimate log𝑂𝑅> !" and their standard errors to use 
as inputs for the Bayesian normal and frequentist models [27].  
Following the same steps as logOR above, we simulated the dataset expressing the 
underlying treatment effect, instead, in terms of risk ratio; 𝛿!" = log𝑅𝑅!". The additional 
concern, particularly for RR, that we need to confine probabilities within 0 and 1. Therefore, 
we inserted, 𝑚𝑎𝑥𝑅𝑅 = exp((𝐵- + 2𝜏) 	× max	(𝑓(𝑋!"))) then we set 𝑝# = 0.5/𝑚𝑎𝑥𝑅𝑅. 
Along with that, we restrict the values of both 𝑝# and 𝑝%; 0.05 < 𝑝# < 0.95 and 𝑝% < 0.97, to 
avoid numerical problems that emerge near the boundaries.  
The Bayesian models were estimated using 1 × 10= iterations with three chains, with a 
burn-in of 1 × 10> and a thinning of one. Given that the simulated data was produced assuming 𝜌 = 0, we did not use bivariate distributions but two independent distributions for 𝛽%! and 𝛽&! 	. 
Each scenario was studied in 1000 simulations. We used the dosresmeta command to fit the 
frequentist model [28]. 
For each method, we estimated the mean bias in the regression coefficients 𝐵%	and 𝐵& 
and 𝜏 as the difference between the true coefficient and the corresponding mean estimated 
value. We computed the mean squared error (MSE) as the sum of the squared bias and the 
variance of the estimates to quantify the variation in sample estimates. As graphical output is 
difficult to monitor in a simulation study, the convergence of the MCMC was quantified here 
only by computing the Gelman statistics y𝑅z; when y𝑅z ≈ 1 the MCMC converges. 
Additionally, we report the coverage for each estimate as the proportion of credible intervals 
that captured the true value. We computed the power to detect 𝐵- ≠ 0 when the estimated 
credible interval does not include zero and the mean of the coefficients’ standard error 
(SE2mean). Finally, we report the Monte Carlo standard error (MCse) to quantify the 
uncertainty of all the quantities presented above. We present the results from OR for bias and 
MSE in the main text whereas the remaining results are presented in the Appendix.   
3.2 Simulation Results 
Table 2 presents the results from the eight scenarios for logORs using splines. Figure 1 shows 
the average estimated curves for scenarios 2 to 4 (results from scenarios 6 to 8  provide similar 
conclusions to those in Figure 1; scenarios 1 and 5 refer to no dose-response association and 
are not presented in the figure). 
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The three estimated dose-response lines are indistinguishable in Figure 1 and all three 
models perform very well and give practically identical results (Table 2).  The binomial 
Bayesian model has a slightly lower bias in the coefficients than the normal Bayesian and the 
frequentist approach in all scenarios. The spline coefficients 	𝐵&  exhibit more bias and are less 
accurate than those of 𝐵%. For both binomial and normal Bayesian models, larger heterogeneity 𝜏 = 0.01 resulted in considerably less bias than when 𝜏 = 0.001.  
Additional results from the simulations are presented in Appendix Table 1-3. The 
coverage of all estimates exceeds 90%. The power to detect a nonzero linear coefficient 𝐵% 
ranges between 85% and 93% when 𝐵% = 0.04 and 100% for 𝐵% = 0.2. The power to detect a 
non-linear association, ranges between 20% and 28% when 𝐵& = 0.03 and is 100% when  𝐵& =−	0.2.  Whereas, the power to detect 𝜏 is very low. The MCMC converged in all simulations 
as y𝑅z < 1.015. Finally, the largest MCse of bias is 9 × 10*>.   
 The results for logRR  are presented in Appendix Figure 11 and Appendix Table 4-6.  
The results of logRR are actually agree with the ones based on logOR. The binomial Bayesian 
model has a slightly less bias and MSE in the coefficients than the normal Bayesian model and 
the one-stage approach in most scenarios. Likewise, the binomial model conveys better 
coverage than the normal Bayesian and the one-stage approach. Regarding power, all 
approaches perform well and the three dose-response curves are identical in Appendix Figure 
11. The coverage in binomial model is much higher than the normal model, whereas the 
opposite is obtained regarding the power. Convergence was good as y𝑅z < 1.05 in all cases. 
The largest MCse of bias is  9 × 10*>. 
4 Dose-response function for antidepressants in major depression 
 
We illustrate the methods by synthesizing the dose-response association reported in 60 
randomized controlled trials (145 arms, 15,174 participants) examining the efficacy and 
tolerability of various doses of SSRI antidepressant drugs [29]. Using a previously validated 
formula, we first transformed the dosages of the different antidepressants into fluoxetine-
equivalents [29]. The response to antidepressant is defined as 50% reduction in symptoms. The 
data and analysis are also available in the GitHub directory. We estimated the dose-response 
relationship using restricted cubic spline with three knots placed at fixed percentiles of the 
dose: 10, 20, and 50 mg/day.  
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The results are displayed in Table 3 and the dose-response curves based on the three 
approaches are shown in Figure 2a. The estimated correlation 𝜌 has a substantial uncertainty. 
The two Bayesian models agree to a large extent with the frequentist approach in the estimated 
linear and spline coefficients and in the precision of the estimations, as shown in results in 
Table 3. There are immaterial differences between the frequentist and the Bayesian models in 
the estimation of heterogeneity and correlation 𝜌; the latter is estimated with large uncertainty 
in Bayesian models.  
In Figure 2b we present the absolute response at each dose level between 1 to 80 mg/day 
estimated using the binomial Bayesian model and the approach presented in section 2.4. The 
uncertainty in the dose-response curve is smaller for smaller doses and gets wider for higher 
doses, as less data is available. The response in the placebo arm was estimated at 37.6% (blue 
line in Figure 2b) [30]. 
We also fit the clustered dose-response model where studies have first being synthesised 
within drug and then across drugs using the binomial likelihood. The coefficients 𝐵%, 𝐵& were 
very similar to those estimated from the model that ignores clusters (see Table 3).  The within-
drug variance 𝜏5!67!(	was estimated 0.0076, a bit smaller than the total heterogeneity from the 
binomial model (𝜏 = 0.0087). There were some differences between the eight drugs as 
indicated from the 𝜏:;65;;( = 0.0050	. However, the dose-response shape is practically 
identical to that of the model that ignores the drug clustering. Finally, the within and between 
cluster correlations are estimated with large uncertainty like in all models. 
We examined the convergence of MCMC for all Bayesian models. Overall, convergence 
is achieved for the all estimated parameters of the three models, see Appendix Table 8-13 and 
Appendix Figure 13-25.  
5 Discussion 
In this paper, we present a hierarchical dose-response meta-analysis model in a Bayesian 
framework. At the first level, the dose-response relationship is fitted within each study. Then 
the curves are combined to get the average dose-response. An additional pooling level can be 
added, if there are different clusters of exposure or drugs. The exact likelihood of the outcome 
(binomial or normal) can be employed if arm-level data is available. Alternatively, the 
observed relative contrast between the study-specific lowest dose and each subsequent dose 
level are assumed to follow a normal likelihood. The model accounts for the covariance of the 
effects of multiple doses and the variability in the dose-response association between studies. 
We showed that the model using the binomial likelihood and normal likelihood performs as 
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well as the frequentist one-stage model and that bias in the coefficients is slightly smaller for 
the binomial Bayesian model.  
Among the limitations common to all Bayesian approaches, two are particularly 
challenging for our model [15, 31]. First, for some scenarios, the estimation can be sensitive to 
the prior choice [32]. In these cases, sensitivity analysis is recommended with either different 
prior distributions or by varying the characteristics (hyperparameters) of the specific prior 
distribution. Second, time-consuming, intensive computation may be required until MCMC 
convergence is achieved. In this context, we emphasize the importance of investigating the 
convergence of MCMC using CODA approaches (e.g. as those presented in appendix).  
Furthermore, the usual challenges of dose-response meta-analysis apply, including ambiguity 
in the categorisation of the exposure, the reporting of different categories by different studies 
or of open-ended categories. These issues are discussed in detail elsewhere [16].  
A strength of our Bayesian approach is its flexibility. We were able to evaluate whether 
studies that examine the same drug are more similar than studies examining different drugs by 
using an extension of our model that adds a layer in the hierarchy according to the specific kind 
of antidepressant that was studied. We were also able to estimate the absolute response to each 
dose [14, 15]. Such estimates can also be obtained in a frequentist setting by using best linear 
unbiased prediction (BULPs) in mixed models, [33, 34]. However, the process is easier in a 
Bayesian framework, which also allows the use of external data to estimate the outcome at zero 
dose. The approach will be particularly valuable in the context of policy- and decision-making 
where the absolute event rates play a more important role than the relative treatment effects.  
The hierarchical structure of the model allows the borrowing of strength across studies 
[12]. Studies that report only one dose-specific effect can thus be included and a nonlinear 
dose-response model fitted. This is also possible in a frequentist setting using the one-stage 
approach, however, our model can be extended to separate between the heterogeneity due to 
variability in dose-response shape and residual between-study heterogeneity. The latter can be 
explored by including covariates that may explain this residual variability; that could lead into 
a dose-response meta-regression. Our model could also be extended to multiple treatments, 
thus offering an alternative to published network meta-analysis models  [35], or it could be 
used to model simultaneously several outcomes with similar dose-response shapes. Another 
potential extension, which we have implemented in our paper, is accounting for cluster of the 
exposure in estimating the dose-response shape. Finally, external knowledge can be 
incorporated, for example, evidence from observational studies. The use of observational data 
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will be particularly relevant when assessing long term outcomes, as the majority of RCTs, in 
psychiatry and elsewhere, are of relatively short duration [17].  
In conclusion, the proposed binomial or normal Bayesian dose-response model provides 
a viable alternative to the existing mixed one-stage model in a frequentist setting. Researchers 
can take advantage of the high flexibility of the model to address complex problems and 
multiple sources of heterogeneity. 
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Table 1 Notation in aggregated-level data in dose-response meta-analysis 𝑖 = 	1, …	, 𝑛𝑠 Study id 𝑗 = 1,… , 𝑛𝑑! Dose levels in study 𝑖 𝑋!" Dose level 𝑗 in study 𝑖  𝑋!# Reference dose in study 𝑖 𝑟!" Number of events in dose 𝑗 within study 𝑖 𝑛!" Sample size in dose 𝑗 within study 𝑖 𝑌!" Within study 𝑖,  the relative effect (on a ln-scale) of 
dose 𝑗 contrasted to the effect in the reference dose 
(𝑋!#) e.g. log odds ratio 𝒀𝒊 = 1𝑌!%, 𝑌!&, … , 𝑌!(()!*%)2 Vector of all dose-specific (ln) relative effects in study 𝑖 
𝑘 = 1,…𝑝 Number of dose transformations associated with the dose-response shape. For a linear shape	𝑝 = 1 and 
for quadratic and restricted cubic splines 𝑝 = 2 𝑐 = 1,2, … , 𝐶 Exposure clusters 
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Table 2. Simulations scenarios for a spline dose-response association assuming random effects for B", 	B#. We 
assume 40 trials reporting aggregated-level data with three dose-levels each. The bias and MSE are reported for 
linear coefficient, spline coefficient and their common heterogeneity (a) B" (b) B# (c) τ, respectively. Bias and 
MSE are divided by 𝟏𝟎𝟑. 
 
(a) Estimate 𝐵% 
 True values  Binomial Bayesian 
 Normal 
Bayesian 
 One-stage 
(frequentist) 
Scenario 𝜏	 𝐵"	 𝐵#	  bias MSE  bias MSE  bias MSE 
S1 0.001 0 0  0.1 0.2  5.5 0.2  4.8 0.2 
S2 0.001 0.04 0  0.2 0.2  4.9 0.2  4.3 0.2 
S3 0.001 0.1 0.03  0.4 0.2  4.5 0.2  4 0.2 
S4 0.001 0.2 -0.2  1 0.1  3.8 0.2  4.1 0.2 
S5 0.01 0 0  0.4 0.2  5.8 0.2  5.2 0.2 
S6 0.01 0.04 0  0.8 0.2  5.6 0.2  5 0.2 
S7 0.01 0.1 0.03  0.9 0.2  4.8 0.2  4.4 0.2 
S8 0.01 0.2 -0.2  2 0.1  4.6 0.2  4.9 0.2 
 
(b) Estimate 𝐵& 
 True values  Binomial Bayesian 
 Normal 
Bayesian 
 One-stage 
(frequentist) 
Scenario 𝜏	 𝐵"	 𝐵#	  bias MSE  bias MSE  bias MSE 
S1 0.001 0 0  -0.3 0.8   -7.1 0.8   -5 0.8 
S2 0.001 0.04 0  -1.2 0.7 
 
-7.5 0.7 
 
-6.1 0.7 
S3 0.001 0.1 0.03  0.7 0.6 
 
-5.7 0.6 
 
-4.3 0.6 
S4 0.001 0.2 -0.2  -0.9 0.5 
 
-4.2 0.5 
 
-4.3 0.5 
S5 0.01 0 0  -0.8 0.9 
 
-7.8 0.9 
 
-6 0.9 
S6 0.01 0.04 0  -0.4 0.7 
 
-6.4 0.7 
 
-4.8 0.7 
S7 0.01 0.1 0.03  0 0.6 
 
-6.3 0.6 
 
-4.8 0.6 
S8 0.01 0.2 -0.2  -2.6 0.5   -5.7 0.6   -5.9 0.6 
 
(c) Estimate 𝜏 
 True values  Binomial Bayesian 
 Normal 
Bayesian 
 
Scenario 𝜏	 𝐵"	 𝐵#	  bias MSE  bias MSE  
S1 0.001 0 0  12.4 0.2   13 0.2   
S2 0.001 0.04 0  11.8 0.2 
 
12.6 0.2 
 
S3 0.001 0.1 0.03  10.5 0.1 
 
11.6 0.2 
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S4 0.001 0.2 -0.2  10.8 0.1 
 
11.7 0.2 
 
S5 0.01 0 0  5.1 0.1 
 
5.5 0.1 
 
S6 0.01 0.04 0  4.4 0.1 
 
5.1 0.1 
 
S7 0.01 0.1 0.03  3.3 0 
 
4.1 0.1 
 
S8 0.01 0.2 -0.2  3.7 0   4.7 0.1   
 
 
Table 3  Dose-response between antidepressants and response to drug.  The model is fitted with restricted cubic 
splines and assuming random dose-response coefficients. Dose is measured as fluoxetine-equivalent in mg/day. 
 
 
 
Figures captions 
 
Figure 1 Dose-response associations corresponding to scenarios 2-4 are in upper three panels. The lower three 
panels are a snapshot in the lager dose range 8-10 to investigate the slight differences between the three 
approaches. 
 
Figure 2 (a) The relative dose-response associations estimated with the three approaches; binomial Bayesian, 
normal Bayesian and one-stage (frequentist) approaches.  Analyses based on 60 randomized clinical trials of 
antidepressant drugs. (b) The absolute response to antidepressants at each dose level over a range of 1 to 80 
mg/day, estimated using the binomial Bayesian model. The dashed lines represent the boundaries of the credible 
region around the absolute dose-response curve. The red lines are the estimated placebo response (solid line) and 
the 95% boundaries of the credible interval (dashed lines). 
 
  
 
Binomial Bayesian Normal Bayesian one-stage (frequentist) Binomial Bayesian with drug 
clusters  
Mean SD Mean SD Mean SE Mean SD 𝐵" 0.0214 0.0024 0.0210 0.0037 0.0209 0.0025 0.0213 0.0036 
𝐵# -0.0397 0.0070 -0.0396 0.0085 -0.0376 0.0060 -0.0387 0.0079 
𝜏 0.0087 0.0028 0.0072 0.0031 𝜏" = 0.0103 𝜏# = 0.0115 - 			𝜏%&'(&) =	0.0076 𝜏*+'%++) = 0.0050 0.0028 0.0040 𝜌 -0.4782 0.4952 -0.2488 0.5652 -1 - 𝜌%&'(&) = −0.3611 		𝜌*+'%++) = −0.1064 0.5153 0.5508 
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Appendix 
 
Tables captions 
 
Appendix Table 1 Assuming odds ratio (OR) as a measure of the treatment effect, 8 scenarios are simulated for a 
spline dose-response association with random effects coefficients. We assume 40 trials reporting aggregated-level 
data with three dose-levels each. The results for the linear coefficient B". 
 
Appendix Table 2 Assuming odds ratio (OR) as a measure of the treatment effect, 8 scenarios are simulated for a 
spline dose-response association with random effects coefficients. We assume 40 trials reporting aggregated-level 
data with three dose-levels each. The results for the spline coefficient B#. 
 
Appendix Table 3 Assuming odds ratio (OR) as a measure of the treatment effect, 8 scenarios are simulated for a 
spline dose-response association with random effects coefficients. We assume 40 trials reporting aggregated-level 
data with three dose-levels each. The results for the common heterogeneity τ. 
Appendix Table 4 Assuming risk ratio (RR) as a measure of the treatment effect, 8 scenarios are simulated for a 
spline dose-response association with random effects coefficients. We assume 40 trials reporting aggregated-level 
data with three dose-levels each. The results for the linear coefficient B". 
 
Appendix Table 5 Assuming risk ratio (RR) as a measure of the treatment effect, 8 scenarios are simulated for a 
spline dose-response association with random effects coefficients. We assume 40 trials reporting aggregated-level 
data with three dose-levels each. The results for the spline coefficient B#. 
Appendix Table 6 Assuming risk ratio (RR) as a measure of the treatment effect, 8 scenarios are simulated for a 
spline dose-response association with random effects coefficients. We assume 40 trials reporting aggregated-level 
data with three dose-levels each. The results for the common heterogeneity τ. 
Appendix Table 7 Results of the three approaches regarding the estimation of linear and spline coefficients B" 
and B#, respectively, in addition to their common heterogeneity τ. These results are based on simulated 
antidepressant dataset from restricted cubic spline dose-response meta-analysis model, the coefficients are set as 
the frequentist estimation that are displayed in Table 3. 
Appendix Table 8 For binomial Bayesian model, the estimated number of burn-in, number of iterations and I 
factor on each chain is presented. 
Appendix Table 9 For normal Bayesian model, the estimated number of burn-in, number of iterations and I factor 
on each chain is presented. 
Appendix Table 10 For binomial Bayesian model with drug-specific class, the estimated number of burn-in, 
number of iterations and I factor on each chain is presented. 
Appendix Table 11 For binomial Bayesian model, the p-value of the stationarity test and halfwidth test and the 
estimated posterior mean of the stationary part of chain is displayed. 
Appendix Table 12 For normal Bayesian model, the p-value of the stationarity test and halfwidth test and the 
estimated posterior mean of the stationary part of chain is displayed. 
Appendix Table 13 For binomial Bayesian model with drug-specific class, the p-value of the stationarity test and 
halfwidth test and the estimated posterior mean of the stationary part of chain is displayed. 
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Figures captions 
 
Appendix Figure 1 The underlying dose-response curve in simulations with its boundaries as true curve ± 2*τ 
(dotted lines) assuming small (red) and large (blue) values for heterogeneity τ. 
 
Appendix Figure 2 Dose-response associations corresponding to scenarios 2-4 are in upper three panels. The 
lower three panels are a snapshot in the lager dose range 8-10 to investigate the slight differences between the 
three approaches.  
 
Appendix Figure 3 Histogram for B4" in a simulation study based on odds ratio (OR)  for the binomial dose-
response meta-analysis model of restricted cubic spline in various scenarios for true B#= (a) 0 (b) 0 (c) 0.03 (d) -
0.2 and true B"= (a) 0 (b) 0.04 (c) 0.1 (d)0.2 (green line)  where in the first and the second columns the true 
heterogeneity is set as τ = 0.001 and τ = 0.01, respectively. 
 
Appendix Figure 4 Histogram for B4#	in a simulation study based on odds ratio (OR)  for the binomial dose-
response meta-analysis model of restricted cubic spline in various scenarios for true B#= (a) 0 (b) 0 (c) 0.03 (d) -
0.2 (green line)  and true B"= (a) 0 (b) 0.04 (c) 0.1 (d)0.2  where in the first and the second columns the true 
heterogeneity is set as τ = 0.001 and τ = 0.01, respectively. 
 
Appendix Figure 5 Histogram for B4"	in a simulation study based on odds ratio (OR)  for the normal dose-response 
meta-analysis model of restricted cubic spline in various scenarios for true B#= (a) 0 (b) 0 (c) 0.03 (d) -0.2 and 
true B"= (a) 0 (b) 0.04 (c) 0.1 (d)0.2 (green line) where in the first and the second columns the true heterogeneity 
is set as τ = 0.001 and τ = 0.01, respectively. 
 
Appendix Figure 6 Histogram for B4#in a simulation study based on odds ratio (OR) for the normal dose-response 
meta-analysis model of restricted cubic spline in various scenarios for true  B#= (a) 0 (b) 0 (c) 0.03 (d) -0.2 (green 
line) and true B"= (a) 0 (b) 0.04 (c) 0.1 (d)0.2  where in the first and the second columns the true heterogeneity is 
set as τ = 0.001 and τ = 0.01, respectively. 
Appendix Figure 7 Histogram for τ5 in a simulation study based on odds ratio (OR) for the binomial dose-response 
meta-analysis model of restricted cubic spline in various scenarios for true B#= (a) 0 (b) 0 (c) 0.03 (d) -0.2 and 
true B"= (a) 0 (b) 0.04 (c) 0.1 (d)0.2  where in the first and the second columns the true heterogeneity is set as τ = 0.001 and τ = 0.01 (green line), respectively. 
 
Appendix Figure 8 Histogram for τ5 in a simulation study based on odds ratio (OR) for the normal dose-response 
meta-analysis model of restricted cubic spline in various scenarios for true B#= (a) 0 (b) 0 (c) 0.03 (d) -0.2 and 
true B"= (a) 0 (b) 0.04 (c) 0.1 (d)0.2  where in the first and the second columns the true heterogeneity is set as τ = 0.001 and τ = 0.01 (green line), respectively. 
 
Appendix Figure 9 Histogram for B4" in a simulation study based on odds ratio (OR) for the one-stage (frequentist) 
dose-response meta-analysis model of restricted cubic spline in various scenarios for true B#= (a) 0 (b) 0 (c) 0.03 
(d) -0.2 and true B"= (a) 0 (b) 0.04 (c) 0.1 (d)0.2 (green line)  where in the first and the second columns the true 
heterogeneity is set as τ = 0.001 and τ = 0.01, respectively. 
 
Appendix Figure 10 Histogram for B4#  in a simulation study based on odds ratio (OR) for the one-stage 
(frequentist) dose-response meta-analysis model of restricted cubic spline in various scenarios for true B#= (a) 0 
(b) 0 (c) 0.03 (d) -0.2 (green line) and true B"= (a) 0 (b) 0.04 (c) 0.1 (d)0.2  where in the first and the second 
columns the true heterogeneity is set as τ = 0.001 and τ = 0.01, respectively. 
Appendix Figure 11 Dose-response associations corresponding to scenarios 2-4 are in the above three panels. The 
lower three panels are a snapshot in the lager dose range 8-10 to identify the slight differences between the three 
approaches. In simulations and model, risk ratio (RR) has been used as a measure of the treatment effect. 
 
Appendix Figure 12 The estimated dose-response curves of the 60 randomized clinical trials that studied the 
effectiveness of antidepressant drugs. 
 
Appendix Figure 13 The distribution of  B4", B4# ,τ5	and		ρ	:of the binomial Bayesian model. 
 
Appendix Figure 14 The distribution of  B4", B4# ,τ5	and		ρ5	of the normal Bayesian model. 
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Appendix Figure 15 The distribution of  B4", B4# , τ5,-./-0 , τ512.,220 , ρ5,-./-0 and  ρ512.,220 of the binomial Bayesian 
model with drug-specific class. 
 
Appendix Figure 16  The trace plot of  B4", B4# ,τ5	and		ρ5	of the binomial Bayesian model. 
 
Appendix Figure 17  The trace plot B4", B4# ,τ5	and		ρ5   of the normal Bayesian model. 
 
Appendix Figure 18  The trace plot of  B4", B4# , τ5,-./-0 , τ512.,220 , ρ5,-./-0 and  ρ512.,220 of the binomial Bayesian 
model with drug-specific class. 
 
Appendix Figure 19  The Geweke plot for each chain of  B4", B4# ,τ5	and		ρ	:	of the binomial Bayesian model. 
 
Appendix Figure 20   The Geweke plot for each chain of  B4", B4# ,τ5	and		ρ	:  of the normal Bayesian model. 
 
Appendix Figure 21  The Geweke plot for each chain of  B4", B4# and τ5,-./-0  of the binomial Bayesian model with 
drug-specific class. 
 
Appendix Figure 22  The Geweke plot for each chain τ512.,220 , ρ5,-./-0 and  ρ512.,220 of the binomial Bayesian 
model with drug-specific class. 
 
Appendix Figure 23 For binomial Bayesian model, Gelman-Rubin plot of the shrink factor ;R4 over the last 
iterations is displayed  B4", B4# ,τ5	and		ρ	: .  
 
Appendix Figure 24  For normal Bayesian model, Gelman-Rubin plot of the shrink factor ;R4 over the last 
iterations is displayed  B4", B4# ,τ5	and		ρ	: . 
 
Appendix Figure 25 For binomial Bayesian model with drug-specific class, Gelman-Rubin plot of the shrink 
factor ;R4 over the iterations is displayed for  B4", B4# , τ5,-./-0 , τ512.,220 , ρ5,-./-0 and  ρ512.,220. 
